Founded in 2013, Eleusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. The company’s comprehensive discovery and development capabilities, together with Andala’s care delivery platform, enable it to target a broad spectrum of unmet needs within psychiatry and beyond psychiatry.
Location: United Kingdom, England, Westminster
Employees: 11-50
Founded date: 2013
Investors 3
Mentions in press and media 4
| Date | Title | Description |
| 20.01.2022 | Psychedelics biotech set to go public via SPAC — pushing IV form of psilocybin into PhI | Psychedelics biotech Eleusis has its eyes on an expansion, and it’s going the SPAC route to get it. The biotech announced earlier today that it’s teaming up with a SPAC born out of asset manager Silver Spike Capital to make... |
| 03.06.2021 | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
| 07.01.2020 | Transforming psychedelics into mainstream medicines | Research on psychedelics, which have been profoundly stigmatized, highly restricted, and tragically undeveloped for more than half a century, is stirring back to life and rekindling scientific, medical, and cultural interest in these compou... |
| - | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |